Jinchang Capsule for type 2 diabetes mellitus of blood-stasis syndrome: a clinical research
Wei Zhu
Abstract
Wei Zhu
Abstract
AIM: To study the clinical efficacy of Jinchang Capsule for the treatment of type 2 diabetes of blood-stasis syndrome. METHODS: From JAN.2001 to OCT.2004, 48 cases were divided randomly into two groups.32 cases in the treatment group were treated with oral Jinchang Capsule combined with Western medicine therapy, and 22 cases in the control group were simply treated with Western medicine therapy, with a course of 8 weeks. The changes of clinical symptoms, and fasting blood glucose (FBG), 2 h post prandial glucose(2hFBG), HbAlc, total cholesterol (Tc), triglycerides (TG), high-density lipoprotein (HDL-c), low-density lipoprotein (LDL-c) levels, and hemorheological parameters were analysed. The safety of the medicine was evaluated also. RESULTS: After treatment, the clinical symptomatic integrals were decreased remarkably in the treatment group (P0.001), with very significant difference compared with the control group (P0.001). Total clinical efficacy was 75% in the treatment group, which was evidently higher than 18.75% in the control group (P0.05). Compared with pretreatment, FBG, 2hPBG, HbA1C obviously dropped in the treatment group (P0.001), with very significant difference between the two groups (P0.01). The levels of TC, TG, LOL-C obviously descended (P0.001),and HDL-C ascended (P0.001) in the treatment group. There was very significant differences in TC, TG, LDL-C (P0.05-0.001). Compared with pretreatment, hemorheological parameters in the treatment group obviously improved (P0.01-0.001). The levels of whole blood viscosity at low-shear rate (10 sec -1 ), plasma viscos}ty, fibrinogen were significafively different (P0. 05-0.01), but with no significant differences in red cell volume, blood viscosity at high-shear rate (120 sec -1 ) between the two groups (P0.05). There was no significant side-effect in the treatment group. CONCLUSION: The results obtained suggest that Jinchang Capsule can improve the clinical symptomatic integrals and remarkably enhance total clinical efficacy. Combining with the basic Western medicinal treatment of diabetes, it can control the obstinate hyperglycemia, and improve fat metabolism as well as bemorheological parameters. It has indicated that Jinchang Capsule has multipurpose therapeutic actions for diabetes mellitus.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
AIM: To study the clinical efficacy of Jinchang Capsule for the treatment of type 2 diabetes of blood-stasis syndrome. METHODS: From JAN.2001 to OCT.2004, 48 cases were divided randomly into two groups.32 cases in the treatment group were treated with oral Jinchang Capsule combined with Western medicine therapy, and 22 cases in the control group were simply treated with Western medicine therapy, with a course of 8 weeks. The changes of clinical symptoms, and fasting blood glucose (FBG), 2 h post prandial glucose(2hFBG), HbAlc, total cholesterol (Tc), triglycerides (TG), high-density lipoprotein (HDL-c), low-density lipoprotein (LDL-c) levels, and hemorheological parameters were analysed. The safety of the medicine was evaluated also. RESULTS: After treatment, the clinical symptomatic integrals were decreased remarkably in the treatment group (P0.001), with very significant difference compared with the control group (P0.001). Total clinical efficacy was 75% in the treatment group, which was evidently higher than 18.75% in the control group (P0.05). Compared with pretreatment, FBG, 2hPBG, HbA1C obviously dropped in the treatment group (P0.001), with very significant difference between the two groups (P0.01). The levels of TC, TG, LOL-C obviously descended (P0.001),and HDL-C ascended (P0.001) in the treatment group. There was very significant differences in TC, TG, LDL-C (P0.05-0.001). Compared with pretreatment, hemorheological parameters in the treatment group obviously improved (P0.01-0.001). The levels of whole blood viscosity at low-shear rate (10 sec -1 ), plasma viscos}ty, fibrinogen were significafively different (P0. 05-0.01), but with no significant differences in red cell volume, blood viscosity at high-shear rate (120 sec -1 ) between the two groups (P0.05). There was no significant side-effect in the treatment group. CONCLUSION: The results obtained suggest that Jinchang Capsule can improve the clinical symptomatic integrals and remarkably enhance total clinical efficacy. Combining with the basic Western medicinal treatment of diabetes, it can control the obstinate hyperglycemia, and improve fat metabolism as well as bemorheological parameters. It has indicated that Jinchang Capsule has multipurpose therapeutic actions for diabetes mellitus.
Key concepts: Medicine, Capsule, Blood stasis, Internal medicine, Hemorheology, Gastroenterology, Blood lipids, Blood viscosity